MedPath

The efficacy of stereotactic body radiation therapy for unresectable hepatocellular carcinoma: a single institution phase II study

Not Applicable
Completed
Conditions
Diseases of the digestive system
Registration Number
KCT0000625
Lead Sponsor
Asan Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
50
Inclusion Criteria

1. Liver function as Child-Pugh class A
2. an Eastern Cooperative Oncology Group (ECOG) score: 0-1
3. the HCC lesions were not suitable for surgery or percutaneous ablative therapies
4. the HCC was = 6 cm across its longest diameter, or = 3 lesions were present with the sum of longest diameters = 6 cm
5. an adequate residual functional liver volume was evident (> 700 mL)
6. Women with childbearing potential and men must agree to use adequate contraception prior to study entry and during study participation
7. The patient must give written, informed consent

Exclusion Criteria

1. Liver function as Child-Pugh class B or C
2. ECOG performance status?>1
3. the HCC was > 6 cm across its longest diameter, or > 3 lesions were present
4. Presence of major vascular invasion or extrahepatic metastasis
5. AST or ALT >5 X upper normal limit (200 IU/L)
6. no adequate residual functional liver volume due to liver cirrhosis or previous hepatic resection (< 700 mL)
7. No sufficient distance between the HCC and adjacent organs at risk, such as the duodenum, stomach, colon, and spinal cord (< 1cm)
8. Uncontrolled ascites or hepatic encephalopathy
9. prior history of external beam radiotherapy in upper abdomen
10. prior history of liver transplantation
11. History of active gastro-duodenal ulcers within the past 3 months
12. Pregnancy or breastfeeding. Patients don't agree to use adequate contraception
13. Previous or concurrent cancer that is distinct in primary site or histology from HCC, except skin cancer within 5 years
14. Any active clinically serious infections (Grade 3, CTCAE ver 4.0)
15. Patients who don't agree to written, informed consent

Study & Design

Study Type
Interventional Study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ocal recurrence rate
Secondary Outcome Measures
NameTimeMethod
Overall survival;Progression-free survival;objective response;recurrence pattern
© Copyright 2025. All Rights Reserved by MedPath